• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishDashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SC 13G/A filed by Wave Life Sciences Ltd. (Amendment)

    2/14/24 4:02:36 PM ET
    $WVE
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $WVE alert in real time by email
    SC 13G/A 1 wvea2_21424.htm 683 CAPITAL MANAGEMENT, LLC wvea2_21424.htm
    UNITED STATES
    SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549
    SCHEDULE 13G
    Under the Securities Exchange Act of 1934
    (Amendment No. 2)*
    Wave Life Sciences Ltd.
    (Name of Issuer)
    $0 par value Ordinary Shares
    (Title of Class of Securities)
    Y95308105
    (CUSIP Number)
    December 31, 2023
    (Date of Event which Requires Filing of this Statement)
    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:
    [   ] Rule 13d-1(b)
    [X] Rule 13d-1(c)
    [   ] Rule 13d-1(d)
    * The remainder of this cover page shall be filled out for a reporting person's initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.
    The information required in the remainder of this cover page shall not be deemed to be "filed" for the purpose of Section 18 of the Securities Exchange Act of 1934 ("Act") or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see Instructions).
    CUSIP No.: Y95308105
           
    1
    NAME OF REPORTING PERSON
    683 Capital Management, LLC
    I.R.S. IDENTIFICATION NO. OF ABOVE PERSON (ENTITIES ONLY)
    2
    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP
    (a) [   ]
    (b) [   ]
    3 SEC USE ONLY
    4
    CITIZENSHIP OR PLACE OF ORGANIZATION
    Delaware
    NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH 5
    SOLE VOTING POWER
    0
    6
    SHARED VOTING POWER
    5,600,000
    7
    SOLE DISPOSITIVE POWER
    0
    8
    SHARED DISPOSITIVE POWER
    5,600,000
    9
    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
    5,600,000
    10
    CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES
    [   ]
    11
    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)
    4.7%
    12
    TYPE OF REPORTING PERSON
    IA
    CUSIP No.: Y95308105
           
    1
    NAME OF REPORTING PERSON
    683 Capital Partners, LP
    I.R.S. IDENTIFICATION NO. OF ABOVE PERSON (ENTITIES ONLY)
    2
    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP
    (a) [   ]
    (b) [   ]
    3 SEC USE ONLY
    4
    CITIZENSHIP OR PLACE OF ORGANIZATION
    Delaware
    NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH 5
    SOLE VOTING POWER
    0
    6
    SHARED VOTING POWER
    5,600,000
    7
    SOLE DISPOSITIVE POWER
    0
    8
    SHARED DISPOSITIVE POWER
    5,600,000
    9
    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
    5,600,000
    10
    CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES
    [   ]
    11
    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)
    4.7%
    12
    TYPE OF REPORTING PERSON
    PN
    CUSIP No.: Y95308105
           
    1
    NAME OF REPORTING PERSON
    Ari Zweiman
    I.R.S. IDENTIFICATION NO. OF ABOVE PERSON (ENTITIES ONLY)
    2
    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP
    (a) [   ]
    (b) [   ]
    3 SEC USE ONLY
    4
    CITIZENSHIP OR PLACE OF ORGANIZATION
    United States of America
    NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH 5
    SOLE VOTING POWER
    0
    6
    SHARED VOTING POWER
    5,600,000
    7
    SOLE DISPOSITIVE POWER
    0
    8
    SHARED DISPOSITIVE POWER
    5,600,000
    9
    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
    5,600,000
    10
    CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES
    [   ]
    11
    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)
    4.7%
    12
    TYPE OF REPORTING PERSON
    IN
    CUSIP No.: Y95308105
    ITEM 1(a). NAME OF ISSUER:
    Wave Life Sciences Ltd.
    ITEM 1(b). ADDRESS OF ISSUER'S PRINCIPAL EXECUTIVE OFFICES:
    7 Straits View #12-00, Marina One East Tower, Singapore 018936
    ITEM 2(a). NAME OF PERSON FILING:
    683 Capital Management, LLC
    683 Capital Partners, LP
    Ari Zweiman
    ITEM 2(b). ADDRESS OF PRINCIPAL BUSINESS OFFICE OR, IF NONE, RESIDENCE:
    The principal business address for each of the Reporting Persons is 1700 Broadway, Suite 4200, New York, NY 10019.
    ITEM 2(c). CITIZENSHIP:
    683 Capital Management, LLC is a Delaware limited liability company. 683 Capital Partners, LP is a Delaware limited partnership. Ari Zweiman is a citizen of the United States.

    ITEM 2(d). TITLE OF CLASS OF SECURITIES:
    $0 par value Ordinary Shares (the Shares)
    ITEM 2(e). CUSIP NUMBER:
    Y95308105
    ITEM 3. IF THIS STATEMENT IS FILED PURSUANT TO SECTION 240.13d-1(b), or 13d-2(b) or (c) CHECK WHETHER THE PERSON FILING IS A:
    (a)
    [ ]
    Broker or dealer registered under Section 15 of the Act (15 U.S.C. 78c);
    (b)
    [ ]
    Bank as defined in Section 3(a)(6) of the Act (15 U.S.C. 78c);
    (c)
    [ ]
    Insurance company as defined in Section 3(a)(19) of the Act (15 U.S.C. 78c);
    (d)
    [ ]
    Investment company registered under Section 8 of the Investment Company Act of 1940 (15 U.S.C 80a-8);
    (e)
    [ ]
    An investment adviser in accordance with 240.13d-1(b)(1)(ii)(E);
    (f)
    [ ]
    An employee benefit plan or endowment fund in accordance with 240.13d-1(b)(1)(ii)(F);
    (g)
    [ ]
    A parent holding company or control person in accordance with 240.13d-1(b)(1)(ii)(G);
    (h)
    [ ]
    A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
    (i)
    [ ]
    A church plan that is excluded from the definition of an investment company under Section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);
    (j)
    [ ]
    A non-U.S. institution in accordance with 240.13d-1(b)(1)(ii)(J);
    (k)
    [ ]
    Group, in accordance with 240.13d-1(b)(1)(ii)(K). If filing as a non-U.S. institution in accordance with 240.13d1(b)(1)(ii)(J), please specify the type of institution:
    ITEM 4. OWNERSHIP
    (a) Amount beneficially owned:
    As of December 31, 2023, 683 Capital Partners, LP beneficially owned 5,600,000 Shares.

    683 Capital Management, LLC, as the investment manager of 683 Capital Partners, LP, may be deemed to have beneficially owned the 5,600,000 Shares beneficially owned by 683 Capital Partners, LP.

    Ari Zweiman, as the Managing Member of 683 Capital Management, LLC, may be deemed to have beneficially owned the 5,600,000 Shares beneficially owned by 683 Capital Management, LLC.
    (b) Percent of class:
    The following percentage is based on 119,011,901 Shares outstanding as of September 30, 2023, as disclosed in the Issuers Prospectus filed pursuant to Rule 424(b)(5) with the Securities and Exchange Commission on December 8, 2023.

    As of December 31, 2023, the Reporting Persons may be deemed to have beneficially owned approximately 4.7% of the outstanding Shares.

    (c) Number of shares as to which the person has:
    (i) sole power to vote or to direct the vote:
    See Cover Pages Items 5-9.
    (ii) shared power to vote or to direct the vote:
    See Cover Pages Items 5-9.
    (iii) sole power to dispose or direct the disposition of:
    See Cover Pages Items 5-9.
    (iv) shared power to dispose or to direct the disposition of:
    See Cover Pages Items 5-9.
    ITEM 5. OWNERSHIP OF FIVE PERCENT OR LESS OF A CLASS:
    If this statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial owner of more than five percent of the class of securities, check the following [X].
    ITEM 6. OWNERSHIP OF MORE THAN FIVE PERCENT ON BEHALF OF ANOTHER PERSON:
    Not applicable.
    ITEM 7. IDENTIFICATION AND CLASSIFICATION OF THE SUBSIDIARY WHICH ACQUIRED THE SECURITY BEING REPORTED ON BY THE PARENT HOLDING COMPANY:
    Not applicable.
    ITEM 8. IDENTIFICATION AND CLASSIFICATION OF MEMBERS OF THE GROUP:
    See Exhibit A of the Schedule 13G filed on May 26, 2022.
    ITEM 9. NOTICE OF DISSOLUTION OF GROUP:
    Not applicable.
    ITEM 10. CERTIFICATION:
    By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect.
    CUSIP No.: Y95308105
    SIGNATURE
    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.
    February 14 2024
    683 Capital Management, LLC
    By:
    /s/ Ari Zweiman
    Name:
    Ari Zweiman
    Title:
    Managing Member
    February 14 2024
    683 Capital Partners, LP
    By:
    /s/ Ari Zweiman
    Name:
    Ari Zweiman
    Title:
    Authorized Person
    February 14 2024
    Ari Zweiman
    By:
    /s/Ari Zweiman
    Name:
    Ari Zweiman
    Title:
    Attention — Intentional misstatements or omissions of fact constitute Federal criminal violations (See 18 U.S.C. 1001).
    Get the next $WVE alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $WVE

    DatePrice TargetRatingAnalyst
    6/11/2025$14.00Outperform
    Raymond James
    4/29/2025$10.00Overweight
    Cantor Fitzgerald
    4/8/2025$18.00Outperform
    Wedbush
    2/25/2025$26.00Buy
    Jefferies
    10/16/2024$22.00Outperform → Strong Buy
    Raymond James
    9/27/2024$10.00 → $13.00Overweight
    JP Morgan
    9/19/2024$11.00Buy
    B. Riley Securities
    9/9/2024$10.00Overweight
    JP Morgan
    More analyst ratings

    $WVE
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Director Verdine Gregory L. sold $208,500 worth of Ordinary Shares (30,000 units at $6.95), decreasing direct ownership by 10% to 282,517 units (SEC Form 4)

      4 - Wave Life Sciences Ltd. (0001631574) (Issuer)

      6/13/25 8:00:04 PM ET
      $WVE
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Director Henry Christian O sold $102,574 worth of Ordinary Shares (10,500 units at $9.77) and exercised 10,500 units of Ordinary Shares at a strike of $9.13 (SEC Form 4)

      4 - Wave Life Sciences Ltd. (0001631574) (Issuer)

      3/21/25 9:00:05 PM ET
      $WVE
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • President and CEO Bolno Paul exercised 169,025 units of Ordinary Shares at a strike of $2.48 and sold $1,617,569 worth of Ordinary Shares (169,025 units at $9.57) (SEC Form 4)

      4 - Wave Life Sciences Ltd. (0001631574) (Issuer)

      3/7/25 9:05:03 PM ET
      $WVE
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $WVE
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Raymond James resumed coverage on Wave Life Sciences with a new price target

      Raymond James resumed coverage of Wave Life Sciences with a rating of Outperform and set a new price target of $14.00

      6/11/25 7:56:30 AM ET
      $WVE
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Cantor Fitzgerald initiated coverage on Wave Life Sciences with a new price target

      Cantor Fitzgerald initiated coverage of Wave Life Sciences with a rating of Overweight and set a new price target of $10.00

      4/29/25 8:13:21 AM ET
      $WVE
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Wedbush initiated coverage on Wave Life Sciences with a new price target

      Wedbush initiated coverage of Wave Life Sciences with a rating of Outperform and set a new price target of $18.00

      4/8/25 9:33:34 AM ET
      $WVE
      Biotechnology: Pharmaceutical Preparations
      Health Care